このエントリーをはてなブックマークに追加
ID 30733
JaLCDOI
FullText URL
Author
Noguchi, Hirofumi
Matsumoto, Shinichi
Matsushita, Masayuki
Kobayashi, Naoya
Tanaka, Koichi
Tanaka, Noriaki
Abstract
The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen is a significant breakthrough that allows the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year ; however, the rate is reduced to 50% at 3 years, attributed to prolonged tacrolimus exposure. Recently, immunosuppression agents such as cyclosporine, mycophenolate mofetil, and the novel agent FTY 720 have been used instead of tacrolimus. Lymphocytedepleting antibodies such as anti-thymocyte globulin, alemtuzumab, and hOKT3gamma 1 (ala, ala) have been launched, and a costimulatory blockade of anti-CD40 monoclonal antibodies and CTLA4-Ig will be attempted in the near future. Moreover, the potential of a novel immunosuppressing peptide could now be realized using new technology called the protein transduction system. In this review, we show some of the most recent contributions to the advancement of knowledge in this field.
Keywords
islet transplantation
steroid-free
Edmonton protocol
protein transduction syst
Amo Type
Review
Published Date
2006-04
Publication Title
Acta Medica Okayama
Volume
volume60
Issue
issue2
Publisher
Okayama University Medical School
Start Page
71
End Page
76
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT